Skip to main content

Table 3 The BP and BD responses to sulforaphane treatment, classified according to initial increased or decreased forced expiratory volume in 1-second (FEV1) response to MCh (mean ± SD). Wilcoxon sign rank test

From: Sulforaphane improves the bronchoprotective response in asthmatics through Nrf2-mediated gene pathways

  BP BD
  Before SF After SF p-for SF effect Before SF After SF p-for SF effect
Overall FEV1 (from Table 2) 15.5 ± 52.7 10.3 ± 57 0.82 32.5 ± 32.7 28.2 ± 28 0.33
Decreased FEV1 response to MCh (n = 29) 37.6 ± 38.0 −0.8 ± 64 0.002 38.3 ± 34.6 23.2 ± 35.1 0.02
Increased FEV1 response to MCh (n = 15) −27.2 ± 51.7 31.7 ± 33 0.004 19.6 ± 25.1 33.4 ± 18.6 0.04